施保利通早期干预儿童腺样体肥大的临床研究  

Clinical Study of Shibaolitong on Early Intervention of Adenoid Hypertrophy in Children

作　　者：成永[1] 张建敏[1] 张方园 朱国际[1] CHENG Yong;ZHANG Jian-min;ZHANG Fang-yuan;ZHU Guo-ji(Children's Hospital of Soochow University,Suzhou,Jiangsu,215003,China)

机构地区：[1]苏州大学附属儿童医院,江苏苏州215003

出　　处：《中国血液流变学杂志》2021年第2期234-236,共3页Chinese Journal of Hemorheology

摘　　要：目的探讨施保利通早期干预儿童腺样体肥大的临床疗效。方法选取2018年10月—2020年10月收治的156例扁桃体肿大的患儿。按照随机分配原则将所有患儿分为2组:对照组78例进行常规治疗,研究组78例应用施保利通对患儿实施早期干预治疗。对比分析两组患儿的治疗效果及不良反应的发生情况。结果研究组的治疗有效率优于对照组(94.87%比76.92%),研究组的不良反应发生率低于对照组(8.97%比29.49%),两组比较差异均有统计学意义(均P<0.05)。结论应用施保利通对腺样体肥大患儿进行早期干预,其治疗效果较为理想,不良反应极少,可以推广应用。Objective To discuss the clinical effect of Shibaolitong on early intervention of children with adenoid hypertrophy.Methods 156 pediatric patients with adenoid hypertrophy admitted from October 2018 to October 2020 were selected.According to the principle of random allocation,they were divided into 2 groups:78 cases in the control group received conventional treatment,and 78 cases in the study group received Shibaolitong for early intervention treatment.Comparative analysis of the treatment effect and adverse reactions of the two groups of children was carried out.Results The treatment effectiveness in the study group was better than that in the control group(94.87%vs.76.92%),and the adverse reaction rate in the study group was lower than that in the control group(8.97%vs.29.49%).The differences between the two groups were statistically significant(P<0.05).Conclusion The application of Shibaolitong for early intervention in children with adenoid hypertrophy has an ideal therapeutic effect with fewer adverse reactions,which can be popularized and applied.

关 键 词：施保利通 早期干预 儿童腺样体肥大 临床效果 

分 类 号：R766[医药卫生—耳鼻咽喉科]